The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter
Open accessAbstract
BACKGROUND: Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects. Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects. METHODS: In two identical multicenter, double-blind, randomized trials, one conducted in Europe (ClinicalTrials.gov number, NCT00259428 [ClinicalTrials.gov] ) and one conducted in the United States, Canada, Australia, South Africa, and Argentina (termed the non-European trial, NCT00259376 [ClinicalTrials.gov] ), we evaluated the efficacy of dronedarone, with 828 patients receiving 400 mg of the drug twice daily and 409 patients receiving placebo. Rhythm was monitored transtelephonically on days 2, 3, and 5; at 3, 5, 7, and 10 months; during recurrence of arrhythmia; and at nine scheduled visits during a 12-month period. The primary end point was the time to the first recurrence of atrial fibrillation or flutter. RESULTS: In the European trial, the median times to the recurrence of arrhythmia were 41 days in the placebo group and 96 days in the dronedarone group (P=0.01). The corresponding durations in the non-European trial were 59 and 158 days (P=0.002). At the recurrence of arrhythmia in the European trial, the mean (+/-SD) ventricular rate was 117.5+/-29.1 beats per minute in the placebo group and 102.3+/-24.7 beats per minute in the dronedarone group (P<0.001); the corresponding rates in the non-European trial were 116.6+/-31.9 and 104.6+/-27.1 beats per minute (P<0.001). Rates of pulmonary toxic effects and of thyroid and liver dysfunction were not significantly increased in the dronedarone group. CONCLUSIONS: Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
A comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Van Gelder, I. C., Hagens, V. E., Bosker, H. A., Kingma, J. H., Kamp, O., Kingma, T., Said, S. A., Darmanata, J. I., Timmermans, A. J. M., Tijssen, J. G. P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021375 · Cited by 2,359
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Amiodarone to Prevent Recurrence of Atrial Fibrillation
Roy, D., Talajic, M., Dorian, P., Connolly, S., Eisenberg, M. J., Green, M., Kus, T., Lambert, J., Dubuc, M., Gagné, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421302 · Cited by 1,143
Self-citationHohnloser, S. H., Kuck, K.-H., & Lilienthal, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03230-x · Cited by 1,134
Self-citationPulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation
Oral, H., Knight, B. P., Tada, H., Özaydın, M., Chugh, A., Hassan, S., Scharf, C., Lai, S. W. K., Greenstein, R., Pelosi, F., et al. (2002) · Circulation · doi:10.1161/hc0902.104712 · Cited by 1,112
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 945
Amiodarone versus sotalol for atrial fibrillation
Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041705 · Cited by 749
Self-citationThe M Cell: Its Contribution to the ECG and to Normal and Abnormal Electrical Function of the Heart
ANTZELEVITCH, C., SHIMIZU, W., YAN, G., SICOURI, S., WEISSENBURGER, J., NESTERENKO, V. V., BURASHNIKOV, A., DI DIEGO, J., SAFFITZ, J., & THOMAS, G. P. (1999) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.1999.tb00287.x · Cited by 611
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
Lafuente-Lafuente, C., Valembois, L., Bergmann, J.-F., & Belmin, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005049.pub4 · Cited by 423
Hohnloser, S. H., Klingenheben, T., & Singh, B. N. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-7-199410010-00009 · Cited by 382
Self-citationDronedarone for prevention of atrial fibrillation: A dose-ranging study
Touboul, P. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00321-x · Cited by 315
Evidence-Based Analysis of Amiodarone Efficacy and Safety
Connolly, S. J. (1999) · Circulation · doi:10.1161/01.cir.100.19.2025 · Cited by 307
Self-citationChun, S. H., Sager, P. T., Stevenson, W. G., Nademanee, K., Middlekauff, H. R., & Singh, B. N. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80799-1 · Cited by 211
Self-citationSun, W., Sarma, J. S. M., & Singh, B. N. (1999) · Circulation · doi:10.1161/01.cir.100.22.2276 · Cited by 188
Self-citationBenditt, D. G., Williams, J. H., Jin, J., Deering, T. F., Zucker, R., Browne, K., Chang-Sing, P., & Singh, B. N. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00275-1 · Cited by 165
Self-citationHohnloser, S. H., & Singh, B. N. (1995) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.1995.tb00368.x · Cited by 158
Self-citationFreedman, L. S., & White, S. J. (1976) · Biometrics · doi:10.2307/2529759 · Cited by 131
Gelder, I. C. V., Hagens, V. E., Kingma, J. H., Bosker, H. A., Otto Kamp, B., Kingma, T., Veeger, N. J. G. M., Bouma, J., TenVergert, E. M., Tijssen, J. G. P., et al. (2002) · PubMed Central · Cited by 125
Self-citationElectrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent
Antzelevitch, C. N., Belardinelli, L., Wu, L., Fraser, H. I., Zygmunt, A. C., Burashnikov, A., Diego, J. M. D., Fish, J. M., Cordeiro, J. M., Goodrow, R. J., et al. (2004) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840400900106 · Cited by 123
Sun, W., Sarma, J. S. M., & Singh, B. N. (2002) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200205000-00008 · Cited by 105
Self-citationThe Molecular and Ionic Specificity of Antiarrhythmic Drug Actions
Nattel, S. (1999) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.1999.tb00673.x · Cited by 97
Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions
Nattel, S., & Singh, B. N. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00697-9 · Cited by 92
Self-citationTsang, T. S. M., & Gersh, B. J. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01245-7 · Cited by 79
New Approaches to Atrial Fibrillation Management: A Critical Review of a Rapidly Evolving Field
Nattel, S., Khairy, P., Roy, D., Thibault, B., Guerra, P. G., Talajic, M. R., & Dubuc, M. (2002) · Drugs · doi:10.2165/00003495-200262160-00005 · Cited by 74
Self-citationAntiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs
Singh, B. N., & Wadhani, N. (2004) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840400900107 · Cited by 40
Self-citationDronedarone for prevention of atrial fibrillation: a dose-ranging study
Touboul, P., Brugada, J., Capucci, A., Crijns, N., Edvardsson, H. J. G. M., & Hohnloser, S. H. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.10.017 · Cited by 39
Self-citationSingh, B. N. (2003) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840300800103 · Cited by 24
Self-citation
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citationVan Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Self-citation2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 2,765
Metadata
- Authors
- Singh, B. N., Connolly, S. J., Crijns, H. J. G. M., Roy, D., Kowey, P. R., Capucci, A., Radzik, D., Aliot, E. M., & Hohnloser, S. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-06
- Volume
- 357
- Issue
- 10
- Pages
- 987-999
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155360142
- Cited by
- 631
- References
- 32
- FWCI
- 48.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.